Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the phase 1 portion of the study is to determine the maximally tolerated dose
(MTD) or recommended dose (RD) and the safety/tolerability of PX-866 in combination
vemurafenib in patients with any advanced BRAF-mutant cancer.
The purpose of the phase 2 portion of the study is to compare progression free survival
(PFS), antitumor activity (response rate), disease control rate (DCR), and the safety and
tolerability of PX-866 in combination with vemurafenib vs. vemurafenib alone in patients with
advanced BRAF-mutant melanoma at the doses recommended from Phase 1.